<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700892</url>
  </required_header>
  <id_info>
    <org_study_id>17-2275</org_study_id>
    <secondary_id>R01HL139369</secondary_id>
    <nct_id>NCT03700892</nct_id>
  </id_info>
  <brief_title>In-vivo Effects of E-cigarette Aerosol on Innate Lung Host Defense</brief_title>
  <acronym>Cinimic</acronym>
  <official_title>In-vivo Effects of E-cigarette Aerosol on Innate Lung Host Defense</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      While e-cigs are commonly represented as safer alternatives to tobacco cigarettes, little is&#xD;
      known regarding the health effects of their short- or long-term use. The responses and the&#xD;
      e-cig components exerting these effects on the airways are largely unknown. This study will&#xD;
      identify if specific e-cig flavors modify respiratory immune responses. This study will&#xD;
      determine the effects of cinnamaldehyde (CA)-containing e-cigarettes on airway epithelial&#xD;
      cell ciliary function (i.e., MCC) in humans. Additionally the study will determine the&#xD;
      effects of CA-containing e-cigarettes on airway immune cells obtained through induced sputum&#xD;
      (SI) after inhalation of CA-containing e-cig aerosols to determine CA-induced effects on a)&#xD;
      immune cell function (e.g., phagocytosis, respiratory burst), b) immune cell surface&#xD;
      phenotype, and c) mediator production in humans in vivo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will evaluate the acute effect of CA-flavored e-cigs on MCC and IS immune cells&#xD;
      in up to 32 healthy, young adults who are current e-cig users with a total of less than 10&#xD;
      pack-years cigarette smoking history. MCC will be measured by gamma scintigraphy at baseline&#xD;
      and following controlled vaping of e-liquids with and without cinnamon flavoring. Two&#xD;
      different e-liquids (one completely devoid and one containing at least 30 mM CA similar to&#xD;
      &quot;Hot Cinnamon Candies&quot; which is commercially available) will be used for two separate&#xD;
      randomized vaping sessions.&#xD;
&#xD;
      The randomization scheme for the two different e-liquids (e-liquids with and without CA) will&#xD;
      be generated by using the Web site Randomization.com (http://www.randomization.com), assigned&#xD;
      treatment Regimen A and B by an assigned study team member, and provided to the study team.&#xD;
      This individual will also be responsible for loading the e-cigarette with the appropriate&#xD;
      solution for that session prior to the vaping sessions.&#xD;
&#xD;
      Participants will undergo baseline testing during the screening visit, which will occur 2-3&#xD;
      weeks prior to the first controlled vaping session. Investigators will also recruit&#xD;
      non-vaping control subjects (n=32), who will only undergo the baseline testing and thus serve&#xD;
      as a non-exposed/non-vaping control group. will aim to recruit similar numbers of males and&#xD;
      females in both cohorts. While investigators cannot guarantee age-matching and sex-matching&#xD;
      in these cohorts, based on our previous studies, investigators do not expect to find&#xD;
      significant age and sex differences in the two cohort. In addition, potential confounders,&#xD;
      such as age, sex, and BMI will be included as covariates in our multivariate analysis.&#xD;
&#xD;
      Observations obtained from the non-vaping control group will provide necessary information on&#xD;
      potential baseline differences in the two cohorts (i.e. current vapers versus non-vaping&#xD;
      controls). These data from the non-vaping control group are important to provide a reference&#xD;
      for any potential CA-induced changes in the vaping group. Hence, there are two stages of the&#xD;
      study:&#xD;
&#xD;
      Stage 1. A cross sectional observational cohort comparison of baseline MCC and IS immune&#xD;
      cells in a reference cohort of n=32 non-vaping control subjects and E-cig cohort of n=32&#xD;
      currently vaping subjects (confounding based on other variables such as BMI, sex, age is&#xD;
      possible for this stage).&#xD;
&#xD;
      Stage 2. A randomized comparison of changes in MCC and IS immune cells after Regimen A (e-cig&#xD;
      us without CA) and Regimen B (e-cig use with CA). The cohort of e-cig users will undergo a&#xD;
      randomized 2-treatment, 2-period, 2-sequence crossover study of CA exposure.&#xD;
&#xD;
      For stage 1, baseline measurements of Tc99m-SC clearance will be used to measure each&#xD;
      subject's normal baseline MCC and IS immune cell characteristics. For both stages, subjects&#xD;
      will be asked to complete a vaping diary to record information on the device and e-liquids&#xD;
      (name/vendor/e-liquids/puffs/device settings) used during their normal vaping sessions for&#xD;
      the entire duration of the study. In addition, for stage 2, participants will be asked to&#xD;
      maintain their current habits for the duration of the study, not to significantly increase or&#xD;
      decrease their vaping patterns, including the nicotine concentrations of their e-liquids.&#xD;
&#xD;
      For stage 2, for each e-cig vaping session (Training and MCC Test Days), subjects will be&#xD;
      asked to follow a laboratory-based protocol involving 6, 5-minute paced vaping segments (1&#xD;
      puff/minute) over a 1 hour time period, vaping the e-liquid with and without CA provided by&#xD;
      us. On each Test Day, participants will undergo the vaping protocol immediately prior to&#xD;
      inhalation of the Tc99m-SC (10 min between end of vaping and inhalation of Tc99m-SC). An&#xD;
      initial deposition scan of Tc99m-SC will then be obtained followed by dynamic imaging of the&#xD;
      lung with subjects seated in front of the gamma camera to determine potential changes in MCC&#xD;
      induced by acute exposure to CA-flavored e- cigarettes. Induced sputum samples will be&#xD;
      collected at baseline, and after each MCC scan.&#xD;
&#xD;
      24 hours after completion of the MCC scans. The two randomized vaping sessions will be&#xD;
      separated by 2-3 weeks. While there are no data providing specific information on the&#xD;
      duration needed to washout the effects of CA on MCC, previous studies examining changes in&#xD;
      MCC following inhalation of other aerosols have shown that this washout period is sufficient&#xD;
      to prevent potential carryover between the two treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Covid-19 has been shown to increase risk associated with vaping. To increase participant safety&#xD;
    and use real world vaping habits, the investigators plan to continue studying vaping effects on&#xD;
    the airways in an observational format.&#xD;
  </why_stopped>
  <start_date type="Actual">October 19, 2018</start_date>
  <completion_date type="Actual">March 3, 2020</completion_date>
  <primary_completion_date type="Actual">March 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Controls will not be randomized and will not receive the study intervention.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The e-liquids will be maintained by an individual not active in the study procedures or analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>CA-induced Changes in Whole Lung MCC</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Absolute values of whole lung MCC at baseline compared to after CA vaping session. Absolute repeat values of Whole lung MCC = average % mucus cleared from the whole lung over a 90-minute period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CA-induced Changes in Regional Lung MCC</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Absolute repeat values of Central and Peripheral lung MCC = average % mucus cleared from the Central and Peripheral lung over a 90-minute period. This will assess clearance rates from the central (C) and peripheral (P) regions as secondary endpoints that may reflect differential effects between a region with relatively more (C) vs. less (P) large bronchial airways.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Polymorphonuclear Leukocytes (PMN) in Induced Sputum</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Percent change of PMNs in vapers from baseline compared to post CA vaping session. Percent change in PMNs in vapers from baseline compared to post PG/VG vaping session are included as an additional comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of Whole Lung MCC for Each Group</measure>
    <time_frame>Start of study, up to three months</time_frame>
    <description>Baseline Differences in Whole lung MCC clearance rates in Non-smokers/Non-vapers as Compared to E-cigarette Users. Absolute group values of Whole Lung MCC =average % mucus cleared from the whole lung over a 90-minute period.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CA-Induced Changes in Immune Cell Function</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Percent change from baseline in phagocytosis</description>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral Blood Mononuclear Cell Analysis</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Percent change in cell counts as compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Serum Analysis of Inflammatory Mediators</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Percent change of mediator expression as compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>CA-Induced Changes in Epithelial Lining Fluid</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Pre-vaping session versus post-vaping session expressed as a percent change</description>
  </other_outcome>
  <other_outcome>
    <measure>CA-Induced Changes in Epithelial Lining Fluid 24 Hours After Vaping Session</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Percent change as compared to post-vaping session sample</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Epithelial Lining Fluid</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Percent change as compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Tidal Volume Subjects Own E-cigarette Device</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Tidal Volume in milliliters</description>
  </other_outcome>
  <other_outcome>
    <measure>Respiratory Rate With Subjects Own E-cigarette Device</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Respiratory Rate in breaths per minute</description>
  </other_outcome>
  <other_outcome>
    <measure>Minute Ventilation With Subjects Own E-cigarette Device</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Minute Ventilation in L/min</description>
  </other_outcome>
  <other_outcome>
    <measure>Inspiratory Flow With Subjects Own E-cigarette Device</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Inspiratory flow in L/min</description>
  </other_outcome>
  <other_outcome>
    <measure>Expiratory Flow With Subjects Own E-cigarette Device</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Expiratory flow in L/min</description>
  </other_outcome>
  <other_outcome>
    <measure>Tidal Volume With Investigator E-cigarette Device</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Tidal Volume in milliliters</description>
  </other_outcome>
  <other_outcome>
    <measure>Respiratory Rate With Investigator E-cigarette Device</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Respiratory Rate in breaths per minute</description>
  </other_outcome>
  <other_outcome>
    <measure>Minute Ventilation With Investigator E-cigarette Device</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Minute Ventilation in L/min</description>
  </other_outcome>
  <other_outcome>
    <measure>Inspiratory Flow With Investigator E-cigarette Device</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Inspiratory flow in L/min</description>
  </other_outcome>
  <other_outcome>
    <measure>Expiratory Flow With Investigator E-cigarette Device</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>Expiratory flow in L/min</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Smoking</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cinnamaldehyde, then PG/VG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PG/VG, then Cinnamaldehyde</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale cinnamaldehyde e-liquid in 6, 5-minute vaping segments (1 puff/minute) over 1 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cinnamaldehyde e-liquid</intervention_name>
    <description>Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
    <arm_group_label>Cinnamaldehyde, then PG/VG</arm_group_label>
    <arm_group_label>PG/VG, then Cinnamaldehyde</arm_group_label>
    <other_name>Cinnamon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PG/VG e-liquid</intervention_name>
    <description>Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
    <arm_group_label>Cinnamaldehyde, then PG/VG</arm_group_label>
    <arm_group_label>PG/VG, then Cinnamaldehyde</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  An equal number of participants who currently use a vaping device and those who do not&#xD;
             use a vaping device&#xD;
&#xD;
          -  Age 18-40&#xD;
&#xD;
          -  Must have a Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second&#xD;
             (FEV₁) of at least 80% of predicted. Participants who fall out of the normal range&#xD;
             will be offered a copy of the test to share with their personal physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any pre-existing lung disease (asthma, cystic fibrosis, etc.)&#xD;
&#xD;
          -  Any significant chronic illness, such as, but not limited to, heart disease,&#xD;
             uncontrolled hypertension, diabetes, auto-immune disease&#xD;
&#xD;
          -  Any use of tobacco products (other than e-cig) in the past 3 months, or a greater than&#xD;
             10 pack year history of smoking cigarettes&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Participants with a history of radiation exposure in the past year which exceeds&#xD;
             annual safe limits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilona Jaspers, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Center for Environmental Medicine, Asthma and Lung Biology</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <results_first_submitted>April 1, 2021</results_first_submitted>
  <results_first_submitted_qc>May 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 10, 2021</results_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>e-cig</keyword>
  <keyword>E-cigarette</keyword>
  <keyword>Electronic cigarette</keyword>
  <keyword>Vaping</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cinnamaldehyde</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, ﬁgures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by an independent review committee (&quot;learned intermediary&quot;) identified for this purpose.&#xD;
Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata&#xD;
Requests for access to individual participant data should be sent to bring44@email.unc.edu or carole.robinette@med.unc.edu. Access will be granted after a data access agreement has been signed with UNC.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT03700892/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>After qualifying, all participants move to the baseline day in which an mucociliary clearance (MCC) scan and sputum are collected for baseline measurements. The vaping participants continue on to the crossover design for CA and PG/VG sessions followed by MCC scans and sputum collections for post exposure measurements.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cinnamaldehyde, Then PG/VG</title>
          <description>Participants will inhale cinnamaldehyde(CA) e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.&#xD;
Cinnamaldehyde e-liquid: Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).&#xD;
PG/VG e-liquid: Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
        </group>
        <group group_id="P2">
          <title>PG/VG, Then Cinnamaldehyde</title>
          <description>Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale cinnamaldehyde e-liquid in 6, 5-minute vaping segments (1 puff/minute) over 1 hour.&#xD;
Cinnamaldehyde e-liquid: Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).&#xD;
PG/VG e-liquid: Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
        </group>
        <group group_id="P3">
          <title>Healthy Controls</title>
          <description>Participants will only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Intervention (Single 1-Day Visit)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (2-3 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (Single 1-Day Visit)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Intervention</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Treated Participants</title>
          <description>All participants inhaled cinnamaldehyde e-liquid or Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in either Period 1 or Period 2 as per randomization schedule.&#xD;
Cinnamaldehyde e-liquid: Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).&#xD;
PG/VG e-liquid: Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
        </group>
        <group group_id="B2">
          <title>Healthy Controls</title>
          <description>Participants will only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CA-induced Changes in Whole Lung MCC</title>
        <description>Absolute values of whole lung MCC at baseline compared to after CA vaping session. Absolute repeat values of Whole lung MCC = average % mucus cleared from the whole lung over a 90-minute period.</description>
        <time_frame>Through study completion, an average of three months</time_frame>
        <population>The healthy control participants only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group. This Primary outcome does not apply to the healthy control group as they did not receive the intervention and only baseline data was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cinnamaldehyde</title>
            <description>Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow.&#xD;
Cinnamaldehyde e-liquid: Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
          </group>
          <group group_id="O2">
            <title>PG/VG</title>
            <description>Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow.&#xD;
PG/VG e-liquid: Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
          </group>
        </group_list>
        <measure>
          <title>CA-induced Changes in Whole Lung MCC</title>
          <description>Absolute values of whole lung MCC at baseline compared to after CA vaping session. Absolute repeat values of Whole lung MCC = average % mucus cleared from the whole lung over a 90-minute period.</description>
          <population>The healthy control participants only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group. This Primary outcome does not apply to the healthy control group as they did not receive the intervention and only baseline data was collected.</population>
          <units>percent clearance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="5"/>
                    <measurement group_id="O2" value="27" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CA-induced Changes in Regional Lung MCC</title>
        <description>Absolute repeat values of Central and Peripheral lung MCC = average % mucus cleared from the Central and Peripheral lung over a 90-minute period. This will assess clearance rates from the central (C) and peripheral (P) regions as secondary endpoints that may reflect differential effects between a region with relatively more (C) vs. less (P) large bronchial airways.</description>
        <time_frame>Through study completion, an average of three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cinnamaldehyde</title>
            <description>Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow.&#xD;
Cinnamaldehyde e-liquid: Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
          </group>
          <group group_id="O2">
            <title>PG/VG</title>
            <description>Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow.&#xD;
PG/VG e-liquid: Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
          </group>
        </group_list>
        <measure>
          <title>CA-induced Changes in Regional Lung MCC</title>
          <description>Absolute repeat values of Central and Peripheral lung MCC = average % mucus cleared from the Central and Peripheral lung over a 90-minute period. This will assess clearance rates from the central (C) and peripheral (P) regions as secondary endpoints that may reflect differential effects between a region with relatively more (C) vs. less (P) large bronchial airways.</description>
          <units>percent clearance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Central Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="12"/>
                    <measurement group_id="O2" value="25" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="3"/>
                    <measurement group_id="O2" value="24" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Polymorphonuclear Leukocytes (PMN) in Induced Sputum</title>
        <description>Percent change of PMNs in vapers from baseline compared to post CA vaping session. Percent change in PMNs in vapers from baseline compared to post PG/VG vaping session are included as an additional comparison.</description>
        <time_frame>Through study completion, an average of three months</time_frame>
        <population>The healthy control participants only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group. This outcome does not apply to the healthy control group as they did not receive the intervention and only baseline data was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Cinnamaldehyde</title>
            <description>Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow.&#xD;
Cinnamaldehyde e-liquid: Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
          </group>
          <group group_id="O2">
            <title>PG/VG</title>
            <description>Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow.&#xD;
PG/VG e-liquid: Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Polymorphonuclear Leukocytes (PMN) in Induced Sputum</title>
          <description>Percent change of PMNs in vapers from baseline compared to post CA vaping session. Percent change in PMNs in vapers from baseline compared to post PG/VG vaping session are included as an additional comparison.</description>
          <population>The healthy control participants only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group. This outcome does not apply to the healthy control group as they did not receive the intervention and only baseline data was collected.</population>
          <units>percent PMN</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="7.2"/>
                    <measurement group_id="O2" value="89.4" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of Whole Lung MCC for Each Group</title>
        <description>Baseline Differences in Whole lung MCC clearance rates in Non-smokers/Non-vapers as Compared to E-cigarette Users. Absolute group values of Whole Lung MCC =average % mucus cleared from the whole lung over a 90-minute period.</description>
        <time_frame>Start of study, up to three months</time_frame>
        <population>Includes all participants who completed the baseline MCC scan.</population>
        <group_list>
          <group group_id="O1">
            <title>E-cigarette Users</title>
            <description>Baseline MCC scans and sputum collection performed prior to randomization.</description>
          </group>
          <group group_id="O2">
            <title>Non-smoker/Non-vaper Healthy Controls</title>
            <description>Baseline MCC scans and sputum collection.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of Whole Lung MCC for Each Group</title>
          <description>Baseline Differences in Whole lung MCC clearance rates in Non-smokers/Non-vapers as Compared to E-cigarette Users. Absolute group values of Whole Lung MCC =average % mucus cleared from the whole lung over a 90-minute period.</description>
          <population>Includes all participants who completed the baseline MCC scan.</population>
          <units>percent clearance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="8"/>
                    <measurement group_id="O2" value="14" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CA-Induced Changes in Immune Cell Function</title>
        <description>Percent change from baseline in phagocytosis</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peripheral Blood Mononuclear Cell Analysis</title>
        <description>Percent change in cell counts as compared to baseline</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Blood Serum Analysis of Inflammatory Mediators</title>
        <description>Percent change of mediator expression as compared to baseline</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CA-Induced Changes in Epithelial Lining Fluid</title>
        <description>Pre-vaping session versus post-vaping session expressed as a percent change</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CA-Induced Changes in Epithelial Lining Fluid 24 Hours After Vaping Session</title>
        <description>Percent change as compared to post-vaping session sample</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Epithelial Lining Fluid</title>
        <description>Percent change as compared to baseline</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Tidal Volume Subjects Own E-cigarette Device</title>
        <description>Tidal Volume in milliliters</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Respiratory Rate With Subjects Own E-cigarette Device</title>
        <description>Respiratory Rate in breaths per minute</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Minute Ventilation With Subjects Own E-cigarette Device</title>
        <description>Minute Ventilation in L/min</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Inspiratory Flow With Subjects Own E-cigarette Device</title>
        <description>Inspiratory flow in L/min</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Expiratory Flow With Subjects Own E-cigarette Device</title>
        <description>Expiratory flow in L/min</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Tidal Volume With Investigator E-cigarette Device</title>
        <description>Tidal Volume in milliliters</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Respiratory Rate With Investigator E-cigarette Device</title>
        <description>Respiratory Rate in breaths per minute</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Minute Ventilation With Investigator E-cigarette Device</title>
        <description>Minute Ventilation in L/min</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Inspiratory Flow With Investigator E-cigarette Device</title>
        <description>Inspiratory flow in L/min</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Expiratory Flow With Investigator E-cigarette Device</title>
        <description>Expiratory flow in L/min</description>
        <time_frame>Through study completion, an average of three months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time a participant signed consent through completion of the second intervention, a total of up to 3 months.</time_frame>
      <desc>Adverse event data included all participants who received at least one dose of Cinnamaldehyde (CA) or Propylene Glycol/Vegetable Glycerin (PG/VG).</desc>
      <group_list>
        <group group_id="E1">
          <title>Cinnamaldehyde</title>
          <description>Participants who inhaled cinnamaldehyde e-liquid in either Period 1 or Period 2 as per randomization schedule.&#xD;
Cinnamaldehyde e-liquid: Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
        </group>
        <group group_id="E2">
          <title>PG/VG</title>
          <description>Participants who inhaled Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in either Period 1 or Period 2 as per randomization schedule.&#xD;
PG/VG e-liquid: Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).</description>
        </group>
        <group group_id="E3">
          <title>Healthy Controls</title>
          <description>Participants will only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Assistant Director of Clinical Research</name_or_title>
      <organization>University of North Carolina at Chapel Hill, Center for Environmental Medicine Asthma and Lung Biology</organization>
      <phone>919 966-5638</phone>
      <email>robinet@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

